Wim Boersma

TL;DR: A simple six point score based on confusion, urea, respiratory rate, blood pressure, and age can be used to stratify patients with CAP into different management groups.

TL;DR: Among adults with non-CF bronchiectasis, the daily use of azithromycin for 12 months compared with placebo resulted in a lower rate of infectious exacerbations, which could result in better quality of life and might influence survival, although effects on antibiotic resistance need to be considered.

TL;DR: Among patients with clinically suspected CAP admitted to non-ICU wards, a strategy of preferred empirical treatment with beta-lactam monotherapy was noninferior to strategies with a beta- lactam-macrolide combination or fluoroquinolone monotherapy with regard to 90-day mortality.

TL;DR: Because of its association with increased late failure and lack of efficacy prednisolone should not be recommended as routine adjunctive treatment in CAP, and a benefit in more severely ill patients cannot be excluded.

TL;DR: There is a need for a clear definition of exacerbations used in clinical trials in patients with bronchiectasis, and an expert conference was convened to develop a consensus definition for use in clinical research.